Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1676
    +0.0019 (+0.17%)
     
  • GBP/USD

    1.2496
    -0.0015 (-0.12%)
     
  • Bitcoin GBP

    51,160.60
    -609.93 (-1.18%)
     
  • CMC Crypto 200

    1,333.09
    -63.44 (-4.38%)
     
  • S&P 500

    5,110.84
    +62.42 (+1.24%)
     
  • DOW

    38,291.62
    +205.82 (+0.54%)
     
  • CRUDE OIL

    83.76
    +0.19 (+0.23%)
     
  • GOLD FUTURES

    2,350.20
    +7.70 (+0.33%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Takeda-Shire Blockbuster Deal Comes With Blockbuster Risks

Takeda-Shire Blockbuster Deal Comes With Blockbuster Risks

Takeda Pharmaceutical Co Ltd. agreed Tuesday to purchase rare-disease drugmaker Shire Plc for $62 billion. But this blockbuster deal comes with blockbuster risk. Takeda will be paying a steep premium and taking on big debt to acquire a company with uncertain prospects. Shire’s hemophilia business provides more than a quarter of its revenue.